在线办公
期刊论坛
主 管
中国人民解放军总医院
主 办
中国人民解放军总医院老年心血管病研究所
中国科技出版传媒股份有限公司
编 辑
中华老年多器官疾病杂志编辑委员会
100853, 北京市复兴路28号
电话:010-66936756
传真:010-66936756
E-mail: zhlndqg@mode301.cn
创刊人 王士雯
总编辑 范利
副总编辑 陈韵岱
执行主编 叶大训
编辑部主任 王雪萍
ISSN 1671-5403
CN 11-4786
创刊时间 2002年
出版周期 月刊
邮发代号 82-408
友情链接
李琪,李丽丽,芮小勇,吴剑卿,戎其飞.不同剂量阿托伐他汀钙对中重度衰弱高龄患者肌少症的影响[J].中华老年多器官疾病杂志,2019,18(4):247~251
不同剂量阿托伐他汀钙对中重度衰弱高龄患者肌少症的影响
Efficacy of different dosages of atrovastatin calcium in ≥80 years sarcopenia patients with moderate to severe frailty
投稿时间:2018-12-12  
DOI:10.11915/j.issn.1671-5403.2019.04.050
中文关键词:  老年人,80以上;衰弱;肌少症
英文关键词:aged, 80 and over; frailty; sarcopenia
基金项目:江苏省干部保健科研项目(BJ16034)
作者单位E-mail
李琪 江苏省钟山康复医院康疗科,南京 210014  
李丽丽 江苏省钟山康复医院康疗科,南京 210014  
芮小勇 江苏省钟山康复医院放射科,南京 210014  
吴剑卿 江苏省人民医院老年医学科,南京 210029  
戎其飞 江苏省钟山康复医院康疗科,南京 210014 rongqifei@126.com 
摘要点击次数: 65
全文下载次数: 152
中文摘要:
      目的 观察不同剂量阿托伐他汀钙对中重度衰弱高龄患者肌少症的影响。方法 入选2016年4月至2018年4月就诊于江苏省钟山康复医院康疗科高龄伴中重度衰弱患者98例,随机数字表法分为20 mg组34例,10 mg组33例,未服药组31例,分别检测服药前、服药12和24个月的总胆固醇(TC)、低密度脂蛋白胆固醇(LDL-C)、甘油三酯(TG)和高密度脂蛋白胆固醇(HDL-C)、握力、4.5 m步行时间、四肢骨骼肌质量指数(ASMI)和衰弱分级。采用SPSS 19.0软件对数据进行分析。组间比较采用t检验、方差分析或χ2检验。结果 服药24个月时,20 mg组患者相比未服药组患者TC[(3.84±0.96) vs(4.36±0.95)mmol/L]、LDL-C[(2.48±1.33) vs(3.19±1.30)mmol/L]、握力[(15.77±3.71) vs(18.58±3.43)kg]和 ASMI[(13.90±2.33) vs(15.27±3.16)kg/m2]降低,相比10 mg组患者TC[(3.84±0.96) vs(4.26±1.03)mmol/L]和LDL-C[(2.48±1.33 ) vs(3.47±1.41)mmol/L]降低,10 mg组患者相比未服药组患者握力[(15.31±4.71) vs(18.58±3.43)]降低,差异均具有统计学意义(P<0.05)。服药24个月20 mg组患者衰弱分级增加一级的发生率为35.3%(12/34),10 mg组患者为18.2%(6/33),未服药组患者为9.7%(3/31),差异具有统计学意义(P=0.036)。结论 他汀类药物可能进一步加剧增龄相关的肌功能下降和衰弱。
英文摘要:
      Objective To investigate the efficacy of different dosages of atrovastatin calcium on very elderly sarcopenia patients with moderate to severe frailty. Methods Ninety-eight very elderly patients with moderate to severe frailty admitted to our Department of Rehabilitation Medicine from April 2016 to April 2018 were recruited in this study. They were randomly divided into 3 groups, taking 20 mg group (n=34), taking 10 mg group (n=33) and drug withdrawl group (n=31). The levels of triglycerides (TG), total cholesterol (TC), low-density lipoprotein cholesterol (LDL-C), and high-density lipoprotein cholesterol (HDL-C) in the peripheral blood, grip strength, 4.5-meter walking time, appendicular skeletal muscle mass index (ASMI), and frailty levels were detected and measured before and after treatment. SPSS statistics 19.0 was used to perform the statistical analysis. Student′s t test, analysis of variance, or Chi-square test was employed for intergroup comparison on different data types. Results After 24 months of treatment, the patients from the 20 mg group had significantly lower TC [(3.84±0.96) vs (4.36±0.95)mmol/L] and LDL-C levels [(2.48±1.33) vs (3.19±1.30)mmol/L], decreased grip strength [(15.77±3.71) vs (18.58±3.43)kg] and ASMI [(13.90±2.33) vs (15.27±3.16)kg/m2] than those from the drug withdrawl group, and the levels of TC and LDL-C were still lower when compared with those of the 10 mg group [(4.26±1.03), (3.47±1.41)mmol/L, all P<0.05]. The grip strength was significantly lower in the 10 mg group than the drug withdrawal group [(15.31±4.71) vs (18.58±3.43)kg, P<0.05]. Moreover, the incidence of frailty level increasing by at least 1 level was 35.3%(12/34) in the 20 mg group, 18.2% (6/33) in the 10 mg group, and 9.7% (3/31) in the withdraw group (P=0.036). Conclusion Statins may further exacerbate age-related declines in muscle function and accelerate frailty.
查看全文    下载PDF阅读器
关闭